Dabrafenib plus Trametinib: A breakthrough in pediatric low-grade glioma therapy.

Background And Aims: Pediatric-type low-grade gliomas (pLGGs) are the most common solid tumors in children, with v-raf murine sarcoma viral oncogene homolog B (BRAF) mutations playing a significant role in their development. Dabrafenib and trametinib are targeted therapies that are recently approved by Food and Drug Administration for pediatric patients with pLGG harboring a BRAF V600E mutation.

Body: This study emphasizes the role of Dabrafenib and Trametinib in pLGG.